2024 Speakers

More speakers to be announced weekly


Rare Community Member

Tanita Allen

Professor, Division of Genetics & Metabolism, University of Wisconsin School of Medicine and Public Health; Director of Newborn Screening Program at Wisconsin State Laboratory of Hygiene

Mei Baker, MD, FACMG

CEO
American Society of Gene and Cell Therapy

David Barrett, JD

Rare Community Member and Associate Professor
Department of Nutrition and Food Studies, College for Community Health, Montclair State University

Mousumi Bose, PhD

Deputy Director, Division of Rare Diseases Research Innovation
NCATS, NIH

P.J. Brooks, PhD

Director, Division of Rare Diseases Research Innovation
NIH

Dominique C. Pichard, MD, MS

Director, Access Policy
Muscular Dystrophy Association

Joel Cartner, Esq.

Center Director for the Center for Drug Evaluation and Research (CDER)
Food and Drug Administration

Patrizia Cavazzoni, M.D.

Head of Global Rare Disease and Member of the Board
Chiesi Pharmaceuticals

Giacomo Chiesi

VP, Data Science
Jazz Pharmaceuticals

Mat Davis

Senior Vice President of Policy and Advocacy
Cystic Fibrosis Foundation

Mary Dwight

Co-Founder & President
Every Cure

David Fajgenbaum, MD, MBA, Msc

Entrepreneur in Residence
Google Ventures

Nicole Gaudelli

Chief Executive Officer
Agios Pharmaceuticals

Brian Goff

President and CEO
Blueprint Medicines

Kate Haviland

Research Director
Real-World Evidence (RWE), Duke-Margolis Institute for Health Policy

Rachele Hendricks-Sturrup, DHSc, MSc, MA

Executive Vice President, Global Product Strategy & Commercialization
Biogen

Rachid Izzar

President, US Business Unit and US Country Head
Takeda

Julie Kim

Co-Founder and Executive Chairman
RallyBio

Martin Mackay, PhD

Director, Center for Biologics Evaluation and Research (CBER)
US Food & Drug Administration (FDA)

Peter Marks, MD, PhD

Chief Medical Officer
FDA

Hilary Marston, MD, MPH

President of R&D
Taysha Gene Therapies

Sukumar Nagendran, MD

Senior Research Scientist
RTI International

Holly Peay, PhD, MS

Executive Partner
Sofinnova Investments

Maha Radhakrishnan, MD

Vice President, Policy & Regulatory Affairs
National Organization for Rare Disorders (NORD)

Heidi Ross, MPH

Science Program Director
CSNK2A1 Foundation

Gabrielle Rushing, PhD

President
Scheer & Company

David Scheer

Chief of Staff and Strategy
Foundation for Sarcoidosis Research

Tricha Shivas

Senior Medical Advisor, Real-World Evidence Analytics, Office of Medical Policy
CDER, FDA

Kimberly Smith, MD, MS

CEO
Center for Innovation & Value Research

Jason Spangler MD, MPH, FACPM

Interim Director, Center for Devices and Radiological Health (CDRH)
US Food & Drug Administration (FDA)

Michelle Tarver, MD, PhD

Managing Principal
Leavitt Partners

Josh Trent

Partner
Goodwin Procter LLP

Matt Wetzel

Partner
OrbiMed

Tal Zaks, MD, PhD

Keep up-to-date on the latest NORD Breakthrough Summit news

Name(Required)